glp-1 drugs market dynamics 2025 Diabetes Treatment | Global Market Analysis Report GLP-1 Drug Market Growth Driven

PEIA opted to pause the program in 2024 citing a $1.3 million per month price tag, inclusive of rebates

Whats the difference between the GLP-1s on the market

They are a tool with a defined cost-benefit envelope that is now well characterized in the peer-reviewed literature

Compounded semaglutide and tirzepatide Compounded versions of semaglutide and tirzepatide represent one of the most popular alternatives to brand-name medications

GLP-1-based therapies led to favorable changes in body composition, with significant reductions in VAT and FBM, particularly during the first six months

However, up to 89% of participants taking efinopegdutide experienced gastrointestinal adverse events (mostly nausea, vomiting and diarrhoea) relative to 28% taking placebo and 60% taking liraglutide (86)